Diligence memo · auto-generated · as of July 2, 2026
Guardant Health, Inc.
Guardant Health, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Guardant Health, Inc. operates in Biotechnology, based in Redwood City.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Guardant Health, Inc. has raised $500M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $320M on 2017-05-09.
Most recent recorded round closed around 2017-05-09.
Valuation (modeled)modeled
Provath models Guardant Health, Inc. at approximately $13.2B (range $1.5B–$28.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.02× the median modeled value of Series D+ Biotechnology companies in 2016–2018 (13 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 9.1 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Humacyte, Inc., Atreca, Inc., Semma Therapeutics, Inc., Braeburn Pharmaceuticals, Inc., Schrodinger, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.